Viking Therapeutics
VKTX
140 hedge funds and large institutions have $92.8M invested in Viking Therapeutics in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 46 increasing their positions, 34 reducing their positions, and 19 closing their positions.
67% more call options, than puts
Call options by funds: $1.06M | Put options by funds: $637K
35% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 34
11% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 19
0% more funds holding
Funds holding: 140 → 140 (0)
6.66% less ownership
Funds ownership: 46.27% → 39.61% (-6.7%)
44% less capital invested
Capital invested by funds: $166M → $92.8M (-$73.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.65M |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$3.05M |
| 3 |
Renaissance Technologies
New York
|
+$2.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.25M |
| 5 |
SCM
Sio Capital Management
New York
|
+$1.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$25.3M |
| 2 |
State Street
Boston,
Massachusetts
|
-$9.93M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.88M |
| 4 |
Rafferty Asset Management
New York
|
-$1.05M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$918K |
VKTX Hedge Fund Activity: Q1 2022 in Review
140 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q1 2022, worth a combined $92.8M — down 44% from $166M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new VKTX positions and 19 closed out — a net gain of 2 holders — while 46 added to existing stakes and 34 trimmed.
The largest buyer was Millennium Management, adding an estimated $4.65M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $25.3M.
- 140 institutional investors held Viking Therapeutics (VKTX) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $92.8M of Viking Therapeutics stock for Q1 2022, down 44% quarter-over-quarter.
- 21 funds opened new Viking Therapeutics positions in Q1 2022 and 19 closed out, a net change of +2 holders.
- The largest Viking Therapeutics buyer in Q1 2022 was Millennium Management, an estimated $4.65M added.
- The largest Viking Therapeutics seller in Q1 2022 was ArrowMark Colorado Holdings, an estimated $25.3M sold.
Based on aggregated 13F filings for Q1 2022.